Anti-IL-5 and anti-IL-4 receptor α treatments have had promising effects in treating patients suffering from chronic rhinosinusitis with nasal polyps and eosinophilic asthma (94, 155, 156). This evidence concerns the gene IL5 and chronic rhinosinusitis.